Beam Therapeutics Inc.
Extracted from this filing and checked against the source text.
Beam Therapeutics Inc. shareholders approved Election of Class III directors at the 2023-06-06 meeting.
Proposal 1 – Each of the following nominees were elected as Class III directors to serve on the Company’s board of directors until the Company’s 2026 annual meeting of stockholders, and until their respective successors have been duly elected and qualified, based on the following votes: Nominee For Against Abstentions Broker Non-Votes John Evans 48,704,446 250,291 124,211 11,303,038 John Maraganore, Ph.D. 41,623,856 7,441,072 14,020 11,303,038View on SEC.gov
Beam Therapeutics Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm at the 2023-06-06 meeting.
Proposal 2 – The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 was ratified, based on the following votes: For Against Abstentions 60,120,184 31,889 229,913View on SEC.gov
Beam Therapeutics Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-06 meeting.
Proposal 3 – The compensation of the Company’s named executive officers was approved, on an advisory basis, based on the following votes: For Against Abstentions Broker Non-Votes 47,040,443 1,996,717 41,788 11,303,038View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.